Betamethasone Dipropionate; Calcipotriene Patent Expiration
Betamethasone Dipropionate; Calcipotriene is used for treating schizophrenia, bipolar disorder, and major depressive disorder. It was first introduced by Leo Pharma As
Betamethasone Dipropionate; Calcipotriene Patents
Given below is the list of patents protecting Betamethasone Dipropionate; Calcipotriene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Wynzora | US11638711 | NULL | Mar 18, 2039 | Mc2 |
| Wynzora | US11696919 | Topical composition | Mar 18, 2039 | Mc2 |
| Enstilar |
US10130640 (Pediatric) | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Dec 10, 2031 | Leo Pharma As |
| Enstilar |
US9119781 (Pediatric) | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Dec 10, 2031 | Leo Pharma As |
| Enstilar | US10130640 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US10617698 | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US10660908 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US10682364 | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US10688108 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US10716799 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US9119781 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US9566286 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Wynzora | US10265265 | Topical composition | Sep 27, 2027 | Mc2 |
| Enstilar | US6753013 | Pharmaceutical composition |
Jan 27, 2020
(Expired) | Leo Pharma As |
| Taclonex | US6753013 | Pharmaceutical composition |
Jan 27, 2020
(Expired) | Leo Pharma As |
| Taclonex | US6787529 | Topical composition |
Jan 27, 2020
(Expired) | Leo Pharma As |
| Taclonex | US5763426 | Crystalline form of a vitamin D analogue |
Jun 09, 2015
(Expired) | Leo Pharma As |
| Taclonex | USRE39706 | Crystalline form of a vitamin D analogue |
Jun 09, 2015
(Expired) | Leo Pharma As |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Betamethasone Dipropionate; Calcipotriene's patents.
Latest Legal Activities on Betamethasone Dipropionate; Calcipotriene's Patents
Given below is the list recent legal activities going on the following patents of Betamethasone Dipropionate; Calcipotriene.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eCofC Notification | 19 Mar, 2024 | US11696919 |
| Mail Patent eCofC Notification | 19 Mar, 2024 | US11638711 |
| Mail Patent eCofC Notification | 19 Mar, 2024 | US11696919 |
| Patent eCofC Notification | 19 Mar, 2024 | US11638711 |
| Email Notification Critical
| 19 Mar, 2024 | US11696919 |
| Recordation of Patent eCertificate of Correction | 19 Mar, 2024 | US11696919 |
| Email Notification Critical
| 19 Mar, 2024 | US11638711 |
| Recordation of Patent eCertificate of Correction | 19 Mar, 2024 | US11638711 |
| Mail Certificate of Correction Memo | 28 Feb, 2024 | US11696919 |
| Mail Certificate of Correction Memo | 28 Feb, 2024 | US11638711 |
Betamethasone Dipropionate; Calcipotriene's Family Patents
